Pear Therapeutics, Inc. Quarterly Cost of Revenue in USD from Q1 2021 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Pear Therapeutics, Inc. quarterly/annual Cost of Revenue history and growth rate from Q1 2021 to Q4 2022.
  • Pear Therapeutics, Inc. Cost of Revenue for the quarter ending December 31, 2022 was $1.75M, a 5.89% increase year-over-year.
  • Pear Therapeutics, Inc. Cost of Revenue for the twelve months ending December 31, 2022 was $8.18M, a 56.4% increase year-over-year.
  • Pear Therapeutics, Inc. annual Cost of Revenue for 2022 was $8.18M, a 56.4% increase from 2021.
  • Pear Therapeutics, Inc. annual Cost of Revenue for 2021 was $5.23M, a 205% increase from 2020.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 $8.18M $1.75M +$97K +5.89% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-31
Q3 2022 $8.09M $2.56M +$435K +20.5% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $7.65M $2.4M +$1.67M +230% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $5.98M $1.48M +$743K +101% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-16
Q4 2021 $5.23M $1.65M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $2.12M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $727K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $738K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.